Is Peri-operative Hyperoxemia a Risk Factor for Postoperative Complications? (HYPEROXIA)

March 2, 2021 updated by: Anil Gupta, Örebro University, Sweden

Is Peri-operative Hyperoxemia a Risk Factor for Postoperative Complications? A Randomised, Prospective Study in Patients Undergoing Vascular Surgery

Patients undergoing vascular surgery are at a significantly high risk of perioperative cardiovascular, cerebral and renal events compared to those undergoing non-vascular surgery. This could be because of co-morbidities that are common in this patient group. Additionally, smoking, which is common in this population, may be a contributing factor.

Oxygen therapy has been used for decades in order to reduce the risk of myocardial infarction and stroke in patients undergoing vascular surgery and pre-existing co-morbidities in the belief that increased inspired oxygen increases oxygen delivery to tissues, thereby reducing the risk for hypoxia and cell death. However, several studies published recently have questioned the routine use of high inspired oxygen concentration (hyperoxia) to improve oxygen delivery, specifically in the neonatal period but possibly even following myocardial infarction. This could be explained by the fact that increasing inspired concentrations of oxygen cause vasoconstriction in cerebral and coronary arteries, thereby reducing blood flow. Additionally, increased oxygen causes excessive production of reactive oxygen species (ROS), and repercussion injury from oxidative stress. The latter can lead to apoptosis (cell death) in myocardial or cerebral neurons. Despite the high risks of administering oxygen when not needed, it is routinely used in hospitals all over the world without a doctors prescription.

This study aims to assess peri-operative complications up to 1 year following vascular surgery in patients randomised to receive high inspired oxygen concentration (endpoint: SpO2 98 - 100%) or minimal inspired O2 concentration (endpoint: SpO2 > 90%).

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Oxygen is probably one of the commonest "non-prescription" drug used in the hospital and its advantage in several situations including carbon monoxide poisoning, central hypoxia and prior to planned intubation in an acute situation are today well-established and commonly used. Oxygen has been frowned upon in the resuscitation of newborn babies because of the risk of retrolental hypoplasia, now well accepted and adopted in clinical practice. Oxygen has also been traditionally used to increase oxygen carrying capacity in patients presenting with an acute coronary syndrome (ACS), to reduce surgical site infections (SSI), to ensure adequate oxygen delivery to tissues in unconscious patients, during cardiac surgery and for postoperative management, specifically after major surgery. Thus, deliberate use of high inspiratory oxygen concentrations (e.g., 80% or above) is recommended in the treatment of specific intoxications, such as with carbon monoxide or cyanide, wherein hyperbaric oxygen should also be considered. In addition, a high oxygen fraction has been suggested to prevent adverse outcomes after surgery and anesthesia, including a reduction in wound infections and postoperative nausea and vomiting (PONV). In critically ill patients, oxygen delivery to the tissues is often compromised, and supplemental oxygen (e.g., face mask with 10 L oxygen per min) is commonly administered to patients with pneumonia, sepsis, acute coronary syndrome, or stroke - in fact, it is estimated that oxygen is given during transport in approximately one-third of all ambulance journeys.

Several reports published recently have questioned many of the "routine" uses of oxygen and some evidence even seems to point towards negative outcomes in some of these conditions. Specifically, excessive oxygen is likely to do more harm than good in the neonatal period, following cardio-pulmonary resuscitation and likely following acute myocardial infarction. Prospective, randomised studies on this important use of oxygen in the preoperative string are, however, lacking in the literature and in view of theoretical risks for hyperoxemia to several organs, the routine use of high oxygen fractions during the peri-operative phase can be questioned.

This study aims to assess peri-operative complications up to 1 year following vascular surgery in patients randomised to receive high inspired oxygen concentration (endpoint: SpO2 98 - 100%) or minimal inspired O2 concentration (endpoint: SpO2 > 90%).

Study Type

Interventional

Enrollment (Actual)

184

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Örebro, Sweden, 701 85
        • University Hospital
      • Örebro, Sweden, 70185
        • Örebro University Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years and older (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients undergoing elective vascular surgery (peripheral or aortic surgery),
  • No language or cognitive disability
  • Written, informed consent

Exclusion Criteria:

  • Patients with COPD/other lung diseases that require preoperative oxygen therapy
  • Patients undergoing carotid artery surgery

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Supplemental Oxygen
Inspired oxygen fraction > 0.5 and SpO2 = 98-100%
Oxygen in sufficient quantity to maintain SpO2 > 98%
Other Names:
  • Medical oxygen
Supplemental Oxygen in sufficient quantity to maintain SpO2 > 90%
Other Names:
  • Medical Air
Experimental: Air or supplemental oxygen
Air or lowest possible inspired concentration of oxygen to maintain SpO2 > 90%
Oxygen in sufficient quantity to maintain SpO2 > 98%
Other Names:
  • Medical oxygen
Supplemental Oxygen in sufficient quantity to maintain SpO2 > 90%
Other Names:
  • Medical Air

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Composite morbidity
Time Frame: 0 - 1 month postoperatively
Major complications such as MACE, TIA/stroke/renal insufficiency/POCD etc
0 - 1 month postoperatively

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Long term outcome (Major complications)
Time Frame: 1 month to 1 year postoperatively
Major complications
1 month to 1 year postoperatively
Specific outcomes (Major adverse cardiac events (MACE))
Time Frame: 0 - 1 year postoperatively
Major adverse cardiac events (MACE)
0 - 1 year postoperatively
Specific outcomes (TIA or stroke)
Time Frame: 0 - 1 year postoperatively
TIA or stroke
0 - 1 year postoperatively
Specific outcomes (renal insufficiency including dialysis or renal failure)
Time Frame: 0 - 1 year postoperatively
renal insufficiency including dialysis or renal failure
0 - 1 year postoperatively

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Complication (Re-operation or bleeding)
Time Frame: 0 - 30 days postoperatively
Re-operation or bleeding
0 - 30 days postoperatively

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Anil Gupta, MD, PhD, Örebro University, Sweden

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2014

Primary Completion (Actual)

December 1, 2020

Study Completion (Actual)

January 1, 2021

Study Registration Dates

First Submitted

November 15, 2014

First Submitted That Met QC Criteria

September 28, 2015

First Posted (Estimate)

September 29, 2015

Study Record Updates

Last Update Posted (Actual)

March 4, 2021

Last Update Submitted That Met QC Criteria

March 2, 2021

Last Verified

March 1, 2021

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Vascular Disease

Clinical Trials on Oxygen

Subscribe